THIS MATERIAL IS A MARKETING COMMUNICATION.
The Rise of Telemedicine: Embracing a New Normalcy
The pandemic has accelerated trends and generated new investment opportunities. Telemedicine is a paradigm.
Telemedicine is the use of modern telecommunications technology that enables a patient to reach medical consultation through an app using artificial intelligence. The process involves a symptom brief then in real-time exchanging the information with a live doctor where diagnosis and recommendation are approved with professional feedback. This new technology integrates with a one-stop-shop where the patient's prescription is registered, and medication is then delivered to the patient's door. All of this is achievable within the comfort of one's home.
Overcoming Healthcare System Challenges
Over the past decade, the healthcare systems in Asian countries have faced fundamental structural issues, including demand-supply imbalances of medical resources, low compensation, and lack of job satisfaction for many medical practitioners in comparison with other major economies.
The increasing popularity of online medical services platforms could remediate the situation of our healthcare system. Telemedicine could:
- Divert less severely ill patients away from tier-one hospitals where resources are tight, by applying a multi-tiered medical system.
- Save public insurance expenses and ease the problem of medication overload.
- Provide other sources of income for medical practitioners.
Digital Healthcare Transformation
Online medical consultation platforms have attracted more users during the COVID-19 crisis. We believe this is a perfect storm to shift offline consumer behavior to an online platform. To facilitate physical isolation and reduce cross-infection, the Chinese government has further supported its adoption, encouraging the utilization of online healthcare services.
We have seen unprecedented demands for telehealth in the wake of the rise of online solutions in healthcare services. For example, China's largest healthcare platform, Ping An Good Doctor, from late-Jan 2020 to early-Feb 2020, witnessed:
- 1.11 billion accumulated visits on the platform1
- 10 times the number of accumulated new registered users1
- 9 times the daily consultations by newly registered users on App1
Chinese Government Support
Earlier in April 2020, the NDRC (National Development and Reform Commission), in conjunction with the Cyberspace Administration, issued a document proposing the development of new digital industries "Internet Plus Healthcare."
The promotion adopts medical insurance services during the prevention and control of COVID-19, supporting the reimbursement of qualified online medical consultations services of common diseases, chronic diseases, and the e-prescription filings for re-visit patients. The guidance urges cooperation between the Provincial Healthcare Security Administration and internet hospitals on the direct online settlement by medical insurance.
Some pilot cities, such as Yinchuan, Guizhou, and Inner Mongolia, have already started promoting internet-related treatments alongside price guidance. More provinces are now joining the bandwagon. The reimbursement rate for online diagnosis lies in the range of RMB6-50 per consultation.
To further promote telehealth, Fuzhou's Municipal Health Commission signed a new agreement with Ping An Good Doctor in October 2019, establishing a centralized internet hospital platform. It was made compulsory for all bricks-and-mortar hospitals in Fuzhou to join.
With an accelerated application on country and city level, we have seen an increase in the usage of online hospitals over the past few months.
In addition to China, digital health platforms in other Asian countries such as Indonesia and India are reporting a surge in activities, too.
Telemedicine Ramps Up in Indonesia
The three most significant digital health platforms in Indonesia, including Alodokter, Halodoc, and GrabHealth (a joint venture between Singapore-based ride-hailer Grab and a Chinese healthcare company), have seen their usage skyrocket in March 2020. Alodokter clocked 32 million website visits in March and over 500,000 free coronavirus consultations since Indonesia's first confirmed case on March 2, according to Alodokter Chief Executive Nathanael Faibis. In April 2020, Grabhealth said daily consultations had nearly doubled to 10,000.
To fight against COVID-19, Indonesia's local government and authorities are actively promoting telehealth services. For example, the Indonesian Government COVID-19 task force announced on March 27 that twenty digital health services platforms would be added to its website, supporting the applications of telehealth services. A digital call centre will be established to direct the traffics of requests. On province-level, 49 million residents in West Java could enjoy the digital health care services, registering for COVID-19 testing through the online platform.
India – Telehealth Becomes a Reality
India formally commenced telemedicine recently. The regulatory body NITI Aayog issued Telemedicine Practice Guidelines on March 25, 2020, enabling Registered Medical Practitioners (RMPs) to provide healthcare remotely.
As the launch is still at an early stage, the regulation only allows registered medical practitioners to provide healthcare remotely via telemedicine. Albeit new technologies such as AI, IoT, data analytic based decision support systems, etc. could support RMPs on patient consultation, diagnosis, or management, the final prescription or counseling has to be directly delivered by the RMP.
The post-COVID New Normal
Even though the business may face challenges in the post-COVID world, they may also bring into being new normalcy. We believe that telemedicine has the potential to be the new norm of the fast-changing medical landscape.
Staying Ahead with Mirae Asset’s Latest Insights
Disclaimer & Information for Investors
No distribution, solicitation or advice: This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated service.
The views and information discussed or referred in this document are as of the date of publication. Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements. In addition, the opinions expressed may differ from those of other Mirae Asset Global Investments’ investment professionals.
Investment involves risk: Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Fund will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Fund and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.
Sources: Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (“MAGI”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.
Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGI as stipulated by local laws and regulations. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Information for EU investors pursuant to Regulation (EU) 2019/1156: This document is a marketing communication and is intended for Professional Investors only. A Prospectus is available for the Mirae Asset Global Discovery Fund (the “Company”) a société d'investissement à capital variable (SICAV) domiciled in Luxembourg structured as an umbrella with a number of sub-funds. Key Investor Information Documents (“KIIDs”) are available for each share class of each of the sub-funds of the Company.
The Company’s Prospectus and the KIIDs can be obtained from www.am.miraeasset.eu/fund-literature . The Prospectus is available in English, French, German, and Danish, while the KIIDs are available in one of the official languages of each of the EU Member States into which each sub-fund has been notified for marketing under the Directive 2009/65/EC (the “UCITS Directive”). Please refer to the Prospectus and the KIID before making any final investment decisions.
A summary of investor rights is available in English from www.am.miraeasset.eu/investor-rights-summary/.
The sub-funds of the Company are currently notified for marketing into a number of EU Member States under the UCITS Directive. FundRock Management Company can terminate such notifications for any share class and/or sub-fund of the Company at any time using the process contained in Article 93a of the UCITS Directive.
Hong Kong: It is intended is for Hong Kong investors. Before making any investment decision to invest in the Fund, Investors should read the Fund’s Prospectus and the information for Hong Kong investors (of applicable) of the Fund for details and the risk factors. The individual and Mirae Asset Global Investments (Hong Kong) Limited may hold the individual securities mentioned. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Securities and Futures Commission.
Singapore: It is not intended for general public distribution. The investment is designed for Institutional investors and/or Accredited Investors as defined under the Securities and Futures Act of Singapore. This document is issued by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Monetary Authority of Singapore. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.
Australia: The information contained in this document is provided by Mirae Asset Global Investments (HK) Limited (“MAGIHK”), which is exempted from the requirement to hold an Australian financial services license under the Corporations Act 2001 (Cth) (Corporations Act) pursuant to ASIC Class Order 03/1103 (Class Order) in respect of the financial services it provides to wholesale clients (as defined in the Corporations Act) in Australia. MAGIHK is regulated by the Securities and Futures Commission of Hong Kong under Hong Kong laws, which differ from Australian laws. Pursuant to the Class Order, this document and any information regarding MAGIHK and its products is strictly provided to and intended for Australian wholesale clients only. The contents of this document is prepared by Mirae Asset Global Investments (HK) Limited and has not been reviewed by the Australian Investments & Securities Commission.
Swiss investors: This document is intended for Professional Investors only. This is an advertising document. The Swiss Representative is 1741 Fund Solutions AG, Burggraben 16, CH-9000 St. Gallen. The Swiss Paying Agent is Tellco AG, Bahnhofstrasse 4, CH-6431 Schwyz. The Prospectus and the Supplements of the Funds, the KIIDs, the Memorandum and Articles of Association as well as the annual and interim reports of the Company are available free of charge from the Swiss Representative.
UK investors: This document is intended for Professional Investors only. The Company is a Luxembourg registered UCITS, recognised in the UK under section 264 of the Financial Services and Markets Act 2000. Compensation from the UK Financial Services Compensation Scheme will not be available in respect of the Fund. The taxation position affecting UK investors is outlined in the Prospectus. This document has been approved for issue in the United Kingdom by Mirae Asset Global Investments (UK) Ltd, a company incorporated in England & Wales with registered number 06044802, and having its registered office at 4th Floor, 4-6 Royal Exchange Buildings, London EC3V 3NL, United Kingdom. Mirae Asset Global Investments (UK) Ltd. is authorised and regulated by the Financial Conduct Authority with firm reference number 467535.
Copyright 2023. All rights reserved. No part of this document may be reproduced in any form, or referred to in any other publication, without express written permission of Mirae Asset Global Investments (Hong Kong) Limited.